EEN Offer: COVID-19 - Chinese company manufacturing COVID-19 nucleic acid detection kit seeks medical distribution partners
A Chinese company offering nucleic acid extraction kits with over 12 years experience has manufactured COVID-19 nucleic acid detection kits. The detection kits have CE IDV certificates and have been widely used in the 2019-nCoV disease tests on clinical specimens in China and other countries. The company is looking to establish long-term distribution agreements with medical distribution companies with proven and documented sales to national health services, hospitals etc.
The Chinese company has over 12 years of experience in developing and manufacturing products for molecular laboratories, including upstream nucleic acid extraction kits with full automation to downstream real time PCR (Polymerase Chain Reaction) diagnostic and research kits, and fluorescence systems. The company has cooperated with more than 2000 hospitals and laboratories with a daily consumption of over 100,000 tests. Globally, its innovative technologies have been introduced into more than 40 countries and regions including Europe, Middle East, Asia, Africa and South and Central America where it has received recognition.
At the outbreak of COVID-19 in January 2020 in China, the company successfully produced the COVID-19 nucleic acid detection kit for clinical specimens to confirm diagnosis. The dual-target gene design is based on the target regions of the 2019-nCoV ORF 1ab (Open Reading Frame 1ab) and the specific conserved sequence encoding of nucleocapsid protein N gene, which detects the 2019-nCoV RNA virus by real-time PCR(Real-time Polymerase Chain Reaction) system with PCR(Polymerase Chain Reaction) mix. The products have been registered in China’s National Medical Products Administration.
The WHO 2019-nCoV (former name) guidelines suggests medical staff in medical institutions pay attention to all suspected cases by the disease definition, collecting respiratory or blood samples for new coronavirus nucleic acid tests, as a reliable method to confirm the diagnosis. The test provides accurate and rapid detection, quickly identifying patients carrying the infection and allowing rapid isolation. It provides evidence for clinical diagnosis and treatment efficacy, monitoring the change of virology to negative, as well as providing reliable data for epidemiological surveillance.
The company is looking to build long-term distribution agreements with professional medical and pharmaceutical suppliers with documented records of working with health services, providing to hospitals, and clinics.
Advantages and Innovations:
- Quick and easy - it can be perfectly matched with their one-tube fast test extraction reagent, which is easy to operate and does not require heating, a change of tubes, and sample preparation can be done in 10 minutes.
- Highly sensitive - Detection sensitivity reaches 200 copies/mL
- Full-process monitoring - The internal standard uses endogenous housekeeping genes to monitor sampling and testing to avoid false negatives results
- Biological safety - The lysate in the reagent has good pathogen inactivation activity and high biological safety.
- High specificity - Using multiple fluorescence detection technology, three fluorescent channels can be used to detect ORF lab, N gene targets and internal standards. Multiple targets ensure specificity and avoid missed detection.
- Strong applicability - It can be perfectly matched with multi-channel quantitative PCR instruments, such as ABI7500,SLAN-96P PCR system, Life Technologies QuantStudio TM 5 PCR system, MA-6000 PCR system etc.
Type and Role of Partner Sought:
Professional medical distribution companies already supplying medico / pharmaceuticals to hospitals and clinics. No startups, or consultancies.
קבלת פרטי התקשרות של החברה יימסרו בכפוף להסכמתה בלבד, ובצירוף פרופיל חברה ופרטי קשר באנגלית של החברה הישראלית
